© 2026 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Why Scientists Are Trying Viruses To Beat Back Bacteria

<em>Clostridium difficile</em>, a bacterium that causes severe diarrhea, can be difficult to treat with antibiotics.
Stefan Hyman
/
University of Leicester
Clostridium difficile, a bacterium that causes severe diarrhea, can be difficult to treat with antibiotics.

Not all viruses are bad for us. Some of them might even help up us fight off bacterial infections someday.

Naturally occurring viruses called bacteriophages attack specific types of bacteria. So researchers at the University of Leicester decided to try and take advantage of phages' bacteria-destroying powers to treat infections with Clostridium difficile, a germ that that can cause severe diarrhea and inflammation of the gastrointestinal tract.

Over the last six years, microbiologist Martha Clokie has isolated hundreds of phages that can kill various strains of C. difficile. Now her lab has teamed up with the pharmaceutical company AmpliPhi to try and turn phages into a product, perhaps a pill, that could be used in humans.

There's no guarantee the approach will work, and so far it hasn't been put to a rigorous test in humans infected with C. difficile. Still, there are some good reasons to check it out.

C. difficile is difficult to treat with antibiotics and is resistant to many of them. Another problem is that the germ often strikes when people take antibiotics to treat other infections. The antibiotics kill good bacteria along with the bad, weakening the gut's defenses against C. diff.

Doctors are using fecal transplants and synthetic poop as possible solutions. But Clokie says that phages could be a useful alternative. "We're simply harnessing the natural enemy of the bacteria," she tells Shots.

Unlike bacteria, Clokie says, phages are very specific about what they attack—right down to the sub-species. In fact, a single phage wouldn't be able to take on all the strains of C. difficle. So Clokie is working to develop a cocktail of viruses that would be able to kill the most common strains.

While the bacteria can evolve and try to outsmart the viruses, the viruses can do the same, Clokie says. They've been involved in this arms race for thousands of years.

As long as they can come up with the right cocktail, there's a very good chance that this phage therapy could work, according to Tim Lu, an associate professor of bioengineering at MIT. "If you know what you want to kill, it's kind of like a silver bullet targeting that bacteria," he tells Shots.

And delivering the phages to a person's gut shouldn't be a challenge, Lu says.

Phages are already approved for use in meat and poultry production. Manufacturers sometimes spray food with phages that target listeria, a common food-borne bacterium.

But using phage therapy in humans is a bit more complicated. "Phages were discovered before antibiotics came around," Lu says. And they've been used in humans, he says. But the problem is, they have yet to be tested in well-controlled clinical trials.

There's also the question of intellectual property. Phages are naturally occurring, and therefore they're difficult to patent, which could discourage pharmaceutical companies.

Ultimately, Lu says, "The science is real." The stuff does work. But, he says, "It's a change in the way we think about treating infections, I think that's the biggest hurdle in a way."

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Federal funding is gone.

Congress has eliminated all funding for public media.

That means $2.1 million per year that Connecticut Public relied on to deliver you news, information, and entertainment programs you enjoyed is gone.

The future of public media is in your hands.

All donations are appreciated, but we ask in this moment you consider starting a monthly gift as a Sustainer to help replace what’s been lost.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

Federal funding is gone.

Congress has eliminated all funding for public media.

That means $2.1 million per year that Connecticut Public relied on to deliver you news, information, and entertainment programs you enjoyed is gone.

The future of public media is in your hands.

All donations are appreciated, but we ask in this moment you consider starting a monthly gift as a Sustainer to help replace what’s been lost.

Related Content